SCHEDULE 13G: JPMorgan Chase & Co. Discloses 6.3% Stake in Keros Therapeutics

JPMorgan Chase & Co. has filed a Schedule 13G, revealing a 6.3% beneficial ownership stake in Keros Therapeutics, Inc. as of March 31, 2025.

Summary

• JPMorgan Chase & Co. reported beneficial ownership of 2,587,146 shares of Keros Therapeutics, Inc. Common Stock.
• This stake represents 6.3% of the total class of securities.
• JPMorgan Chase & Co. holds sole voting power and sole dispositive power over all 2,587,146 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Keros Therapeutics, Inc.
• The filing was made by JPMorgan Chase & Co. as a parent holding company, with subsidiaries including J.P. Morgan Securities LLC, JPMorgan Chase Bank, National Association, J.P. Morgan Securities PLC, and J.P. Morgan Markets Limited.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive due to the disclosure of a significant institutional stake by a reputable financial entity, which can be interpreted as a vote of confidence, although the filing itself is purely factual and regulatory.

Positives

• The disclosure of a significant 6.3% stake by a major financial institution like JPMorgan Chase & Co. can signal institutional confidence or interest in Keros Therapeutics, Inc.

Future Outlook

This document is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Keros Therapeutics, Inc.'s future operations or financial performance.

Industry Context

This filing reflects ongoing institutional investment activity within the biotechnology and pharmaceutical sectors, where major financial entities like JPMorgan Chase & Co. acquire significant stakes in publicly traded companies like Keros Therapeutics, Inc. for investment purposes.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing investor sentiment and trading activity.

Key Dates

Keywords

Keros Therapeutics, JPMorgan Chase & Co., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Biotechnology, Pharmaceuticals